These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 15077994

  • 1. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.
    Schito GC, Marchese A, Elkharrat D, Farrell DJ, PROTEKT Study Group.
    J Chemother; 2004 Feb; 16(1):13-22. PubMed ID: 15077994
    [Abstract] [Full Text] [Related]

  • 2. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG, Brown SD, Farrell DJ.
    Ann Clin Microbiol Antimicrob; 2008 Jan 11; 7():1. PubMed ID: 18190701
    [Abstract] [Full Text] [Related]

  • 3. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
    Farrell DJ, Jenkins SG.
    J Antimicrob Chemother; 2004 Aug 11; 54 Suppl 1():i17-22. PubMed ID: 15265832
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.
    Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D.
    Antimicrob Agents Chemother; 2004 Aug 11; 48(8):3169-71. PubMed ID: 15273142
    [Abstract] [Full Text] [Related]

  • 5. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
    Felmingham D, Reinert RR, Hirakata Y, Rodloff A.
    J Antimicrob Chemother; 2002 Sep 11; 50 Suppl S1():25-37. PubMed ID: 12239226
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW, Brown SD.
    Clin Ther; 2004 Apr 11; 26(4):522-30. PubMed ID: 15189749
    [Abstract] [Full Text] [Related]

  • 7. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
    Farrell DJ, Morrissey I, Bakker S, Felmingham D.
    J Antimicrob Chemother; 2002 Sep 11; 50 Suppl S1():39-47. PubMed ID: 12239227
    [Abstract] [Full Text] [Related]

  • 8. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A, Koncan R, Vitali LA, Cornaglia G.
    J Antimicrob Chemother; 2007 Jun 11; 59(6):1171-6. PubMed ID: 17405779
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F, Carnegy F, Willcock J, Amyes S.
    J Antimicrob Chemother; 2004 May 11; 53(5):793-6. PubMed ID: 15056640
    [Abstract] [Full Text] [Related]

  • 10. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
    Brown SD, Farrell DJ, Morrissey I.
    J Clin Microbiol; 2004 Nov 11; 42(11):4980-7. PubMed ID: 15528684
    [Abstract] [Full Text] [Related]

  • 11. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A, Koncan R, Bahar G, Cornaglia G.
    J Chemother; 2007 Oct 11; 19(5):500-7. PubMed ID: 18073148
    [Abstract] [Full Text] [Related]

  • 12. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.
    Jenkins SG, Farrell DJ, Patel M, Lavin BS.
    J Infect; 2005 Dec 11; 51(5):355-63. PubMed ID: 15950288
    [Abstract] [Full Text] [Related]

  • 13. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.
    Kim NJ, Park SJ, Choi SH, Lee MS, Choo EJ, Kwak YG, Woo JH, Ryu J, Jeong JY, Kim YS.
    Microb Drug Resist; 2005 Dec 11; 11(3):260-5. PubMed ID: 16201929
    [Abstract] [Full Text] [Related]

  • 14. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb 11; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 15. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.
    Brown SD, Farrell DJ.
    J Antimicrob Chemother; 2004 Aug 11; 54 Suppl 1():i23-9. PubMed ID: 15265833
    [Abstract] [Full Text] [Related]

  • 16. Activity of telithromycin against multi-drug resistant Streptococcus pneumoniae and molecular characterization of macrolide and tetracycline resistance determinants.
    Cascone C, Mezzatesta ML, Santagati M, Cafiso V, Nicoletti G, Stefani S.
    J Chemother; 2005 Oct 11; 17(5):502-8. PubMed ID: 16323438
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG, Johanson C, Hisanaga T, Mendoza C, Laing N, Noreddin A, Wierzbowski A, Hoban DJ.
    J Antimicrob Chemother; 2004 Dec 11; 54(6):1072-7. PubMed ID: 15531596
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD, Rybak MJ.
    J Antimicrob Chemother; 2004 Aug 11; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K, Farrell DJ.
    Ann Clin Microbiol Antimicrob; 2007 Aug 13; 6():7. PubMed ID: 17697316
    [Abstract] [Full Text] [Related]

  • 20. [Streptococcus pneumoniae strains resistance to macrolide, lincosamide, streptogramin, oxazolidinone and ketolide].
    Sener B, Köseoğlu O, Fişenk I, Hasçelik G, Günalp A.
    Mikrobiyol Bul; 2002 Apr 13; 36(2):125-31. PubMed ID: 12652863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.